Table 3.
Outcomes
| Study | LC % |
OS %
1 year |
Median OS (months) | Median PFS (months) | Toxicity scale | Acute toxicity G ≥ 3 % | Late toxicity G ≥ 3 % |
| Barney et al. 201224 | Crude: 100 | 73.0 | NR | NR | CTCAE vs 3.0 | 0.0 | Biliary stenosis: 8.3 Liver failure: 8.3 (G5) |
| Ibarra et al. 201223 | NR | 45.0 | 11 | 4.2 | CTCAE vs 3.0 | 7.0 | 0.0 |
| Jung et al. 201422 | 1y: 85.0, 2y: 72.0 |
45.0 2y: 20.0 |
10 | NR | CTCAE vs 4.0 | 0.0 | Cholangitis: 8.6 Biliary stenosis: 1.7 Gastric perforation: 1.7 Gastric ulcer :1.7 |
| Kopek et al. 201026 | 1y: 84.0 | NR | 10.6 | 6.7 | CTCAE vs 3.0/World Health Organization | Nausea: 3.7 Pain: 7.4 Liver enzyme: 55.5 |
Gastroduodenal ulceration: 22.2 Duodenal stenosis: 11.0 |
| Mahadevan et al. 201520 | 1y: 88.0 | 58.0, 2y: 31.0 |
17 | 10 | NR | 0.0 | Duodenal ulceration:5.9 Cholangitis:1.7 Liver abscess:1.7 |
| Polistina et al. 201125 | NR | 80.0 2y: 80.0 |
b 35.5 | 30.0 | CTCAE vs 3.0 | 0.0 | 0.0 |
| Sandler et al. 201619 | 1y: 78.0 2y :47.0 |
59.0 2y: 33 |
15.7 | 16.8 | CTCAE vs 4.0 | Duodenal stenosis: 3.2 | Duodenal stenosis: 6.4 Duodenal hemorrhage:10.3 Pain: 3.2 |
| Shen et al. 201718 | Crude: 89.3 | 57.1 2y:32.1 |
15 | 11 | CTCAE vs 4.0 | 0.0 | 0.0 |
| Tse et al. 200827 | NR | 58.0 | 15 | NR | CTCAE vs 3.0 | Liver Enzymes:20.0 Transient biliary obstruction: 20.0 |
Bowel obstruction: 10.0 |
| Welling et al. 201421 | NR | 83.0 (1) | NR | NR | SAEs | Cholangitis: 5.0 Dehydration: 7.0 Palmar-plantar erythrodysesthesia: 43.0 Diarrhea: 14.0 Wound infection post-surgery: 14.0 |
NR |
CTCAE, common terminology criteria for adverse events; G, grade; NR, not reported; OS, overall survival; PFS, progression free survival; SAEs, Serious Adverse Events.
(1): in six transplanted patients.
a
Median local progression free survival.
b
calculated from time of diagnosis.